Investigating specific proteins associated with asthma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the changes in gene expression of transgelin-2, metallothionein-2, and ezrin in individuals diagnosed with asthma. The researchers will assess the correlation of these proteins with established asthma diagnostic markers, such as pulmonary function tests and inflammatory markers. By comparing asthmatic patients with healthy volunteers, the study seeks to enhance understanding of the molecular mechanisms underlying asthma. No interventions will be administered, as the focus is on observational data collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males or females, aged 14-75 years;
2. Patients with a definite diagnosis of bronchial asthma;
3. The diagnosis of asthma according to the Global Initiative for Asthma (GINA), with positive bronchodilator responsiveness (reversibility) test;
4. Healthy volunteers without respiratory symptoms such as cough, wheezing, chest tightness or dyspnea;
5. Agree with all procedures in this trial by signing a written informed consent form.

Exclusion Criteria:

1. Patients with chronic obstructive pulmonary disease or other airway disease;
2. Complicated with other severe primary diseases (including hypertension, cancer, hyperthyroidism, bronchiectasia, cardiac insufficiency) and conditions that would prevent participation in the trial or put the participant at risk;
3. Women who are known to be pregnant or breastfeeding;
4. Not willing to participate;
5. Psychiatric history and neurological disorders can not work normally;
6. Other conditions that the researcher considers inappropriate to participate in this study.

Where it's running

• Xiangya Hospital, Central South University
  Changsha, Hunan, China Recruiting
• Yueyang Hospital, Shanghai University of Traditional Chinese Medicine
  Shanghai, Shanghai Municipality, China Not yet recruiting

Study contacts

• Study coordinator: Lei-Miao Yin, MD
• Email: collegeylm@shutcm.edu.cn
• Phone: 13774384237

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

• GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)

  A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · San Diego, California and 6 other locations · NCT07782996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.